All In Biotech

Drug Trial Radar · NCT00651612

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

Last checked: Nov 19, 2026Latest source record: Apr 3, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 604 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

604

Actual

Start

Nov 2005

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Apr 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic SolutionDrug

    Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)

  • Concurrent brimonidine 0.2% and 0.5% timololDrug

    Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Newport Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.